Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dantonic Pill
- Development stage
- Unknown
- Lead developer
- Tasly Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Dantonic Pill (T89) is a modernized botanical drug developed by Tasly Pharmaceutical Company. It is a formulation of extracts from Radix Salviae Miltiorrhizae (Danshen) and Radix Notoginseng (Sanqi), with Borneol added as an absorption enhancer. Primarily indicated for chronic stable angina pectoris due to coronary heart disease, it also shows potential in preventing and managing atherosclerosis. Its mechanism involves the downregulation of circulating adhesion molecules (CAMs) such as ICAM-1, VCAM-1, and E-selectin in the vascular endothelium, thereby inhibiting leukocyte adhesion and atherogenesis while improving coronary blood flow and microcirculation. It was the first traditional Chinese medicine to complete a Phase III clinical trial under an FDA IND in the United States.
- Brand names
- DantonicCardiotonic Pill
- Other names
- Compound Danshen Dripping PillCDDP
02
Targets
ICAM1 (Intercellular Adhesion Molecule 1)SELE (E-selectin)VCAM1 (Vascular cell adhesion molecule 1)
Beyond the preview
Go deeper on Dantonic Pill.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dantonic Pill.